CO2023009153A2 - Anticuerpos split que se unen a células cancerosas y dirigen radionúclidos a dichas células - Google Patents
Anticuerpos split que se unen a células cancerosas y dirigen radionúclidos a dichas célulasInfo
- Publication number
- CO2023009153A2 CO2023009153A2 CONC2023/0009153A CO2023009153A CO2023009153A2 CO 2023009153 A2 CO2023009153 A2 CO 2023009153A2 CO 2023009153 A CO2023009153 A CO 2023009153A CO 2023009153 A2 CO2023009153 A2 CO 2023009153A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- bind
- cells
- split
- cancer cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21151245 | 2021-01-12 | ||
| PCT/EP2022/050359 WO2022152656A1 (en) | 2021-01-12 | 2022-01-10 | Split antibodies which bind to cancer cells and target radionuclides to said cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023009153A2 true CO2023009153A2 (es) | 2023-07-21 |
Family
ID=74175694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0009153A CO2023009153A2 (es) | 2021-01-12 | 2023-07-10 | Anticuerpos split que se unen a células cancerosas y dirigen radionúclidos a dichas células |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240082437A1 (enExample) |
| EP (1) | EP4277705A1 (enExample) |
| JP (1) | JP2024504931A (enExample) |
| KR (1) | KR20230131204A (enExample) |
| CN (1) | CN116829593A (enExample) |
| AR (1) | AR124609A1 (enExample) |
| AU (1) | AU2022207615A1 (enExample) |
| CA (1) | CA3206466A1 (enExample) |
| CL (1) | CL2023001989A1 (enExample) |
| CO (1) | CO2023009153A2 (enExample) |
| CR (1) | CR20230385A (enExample) |
| IL (1) | IL304224A (enExample) |
| MX (1) | MX2023008084A (enExample) |
| PE (1) | PE20240690A1 (enExample) |
| TW (1) | TW202241962A (enExample) |
| WO (1) | WO2022152656A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025176614A1 (en) | 2024-02-20 | 2025-08-28 | F. Hoffmann-La Roche Ag | Novel pre-targeting antibodies and uses thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5846535A (en) | 1990-10-12 | 1998-12-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP2003505082A (ja) | 1999-07-26 | 2003-02-12 | ジェネンテック・インコーポレーテッド | 新規なポリヌクレオチドとその使用法 |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| EP2248892B1 (en) | 2003-01-22 | 2015-04-22 | Roche Glycart AG | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7982011B2 (en) | 2003-11-25 | 2011-07-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PL1871805T3 (pl) | 2005-02-07 | 2020-03-31 | Roche Glycart Ag | Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania |
| US20090226444A1 (en) | 2005-12-21 | 2009-09-10 | Micromet Ag | Pharmaceutical antibody compositions with resistance to soluble cea |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| WO2010099536A2 (en) | 2009-02-27 | 2010-09-02 | Massachusetts Institute Of Technology | Engineered proteins with high affinity for dota chelates |
| EP2478013B1 (en) | 2009-09-16 | 2018-10-24 | F.Hoffmann-La Roche Ag | Coiled coil and/or tether containing protein complexes and uses thereof |
| PE20141017A1 (es) | 2011-03-02 | 2014-08-25 | Roche Glycart Ag | Anticuerpos del cea |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| CA2861003C (en) * | 2012-01-13 | 2023-03-28 | Julius-Maximilians-Universitat Wurzburg | Dual antigen-induced bipartite functional complementation |
| MX360352B (es) | 2012-02-15 | 2018-10-30 | Hoffmann La Roche | Cromatografia de afinidad basada en receptores fc. |
| LT2961771T (lt) | 2013-02-26 | 2020-03-10 | Roche Glycart Ag | Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams |
| UA118029C2 (uk) | 2013-04-29 | 2018-11-12 | Ф. Хоффманн-Ля Рош Аг | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| EP3224275B1 (en) | 2014-11-14 | 2020-03-04 | F.Hoffmann-La Roche Ag | Antigen binding molecules comprising a tnf family ligand trimer |
| WO2016172485A2 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
| PE20180484A1 (es) | 2015-10-02 | 2018-03-07 | Hoffmann La Roche | Moleculas biespecificas de union a antigeno activadoras de celulas t |
| FI3377103T4 (fi) * | 2015-11-19 | 2025-04-16 | Revitope Limited | Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten |
| US20210070846A1 (en) * | 2017-12-21 | 2021-03-11 | Gernot Stuhler | Specific dosage regimen for hemibody therapy |
| TWI874314B (zh) | 2018-04-16 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 螯合型放射核種之抗體 |
| AR119382A1 (es) * | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| CR20230076A (es) * | 2020-07-10 | 2023-03-13 | Hoffmann La Roche | Anticuerpos que se unen a células cancerosas y dirigen radionucleótidos a dichas células |
-
2022
- 2022-01-10 JP JP2023541914A patent/JP2024504931A/ja active Pending
- 2022-01-10 CN CN202280009557.4A patent/CN116829593A/zh active Pending
- 2022-01-10 MX MX2023008084A patent/MX2023008084A/es unknown
- 2022-01-10 KR KR1020237023297A patent/KR20230131204A/ko active Pending
- 2022-01-10 PE PE2023002036A patent/PE20240690A1/es unknown
- 2022-01-10 CA CA3206466A patent/CA3206466A1/en active Pending
- 2022-01-10 US US18/271,835 patent/US20240082437A1/en active Pending
- 2022-01-10 CR CR20230385A patent/CR20230385A/es unknown
- 2022-01-10 WO PCT/EP2022/050359 patent/WO2022152656A1/en not_active Ceased
- 2022-01-10 AU AU2022207615A patent/AU2022207615A1/en not_active Abandoned
- 2022-01-10 EP EP22700173.2A patent/EP4277705A1/en active Pending
- 2022-01-11 TW TW111101051A patent/TW202241962A/zh unknown
- 2022-01-12 AR ARP220100054A patent/AR124609A1/es not_active Application Discontinuation
-
2023
- 2023-07-03 IL IL304224A patent/IL304224A/en unknown
- 2023-07-06 CL CL2023001989A patent/CL2023001989A1/es unknown
- 2023-07-10 CO CONC2023/0009153A patent/CO2023009153A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023001989A1 (es) | 2024-02-02 |
| CN116829593A (zh) | 2023-09-29 |
| MX2023008084A (es) | 2023-07-13 |
| AR124609A1 (es) | 2023-04-12 |
| US20240082437A1 (en) | 2024-03-14 |
| WO2022152656A1 (en) | 2022-07-21 |
| AU2022207615A1 (en) | 2023-07-13 |
| JP2024504931A (ja) | 2024-02-02 |
| IL304224A (en) | 2023-09-01 |
| TW202241962A (zh) | 2022-11-01 |
| CR20230385A (es) | 2023-09-25 |
| CA3206466A1 (en) | 2022-07-21 |
| PE20240690A1 (es) | 2024-04-10 |
| EP4277705A1 (en) | 2023-11-22 |
| KR20230131204A (ko) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001879A (es) | Proteínas de fijación al antígeno que se dirigen a antígenos compartidos. | |
| CO2022001021A2 (es) | Anticuerpos que se unen a células cancerosas yque dirigen radionucleidos a dichas células | |
| BR112018014760A2 (pt) | anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos | |
| BR112022009723A2 (pt) | Anticorpos específicos para cd47, pd-l1, e usos dos mesmos | |
| MX394121B (es) | Anticuerpos que se unen a cd39 y sus usos | |
| MX2020014158A (es) | Anticuerpos anti proteína de muerte programada 1 (pd-1) y usos de estos. | |
| BR112019003129A2 (pt) | composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer. | |
| CO2021000497A2 (es) | Proteína de unión al antígeno anti-steap1 | |
| CL2018002034A1 (es) | Proteínas de unión a antígeno que se unen a pd-l1. | |
| CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
| PE20171764A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123 | |
| CO2019010230A2 (es) | Formulaciones que comprenden proteínas de unión a pd-1 y métodos para realizarlas | |
| AR121370A1 (es) | Anticuerpos anti-cd19 humano | |
| CO2019003759A2 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos | |
| CO2021000386A2 (es) | Anticuerpos humanizados contra psma | |
| AR120093A1 (es) | Anticuerpos anti-ceacam y usos de los mismos | |
| MX2023012995A (es) | Anticuerpo biespecífico que se enlaza específicamente a cd47 y pd-l1. | |
| CO2023009153A2 (es) | Anticuerpos split que se unen a células cancerosas y dirigen radionúclidos a dichas células | |
| CL2022001673A1 (es) | Anticuerpos contra la integrina alfa 11 beta 1. | |
| UY39912A (es) | Radioconjugados anti-psma y usos de estos | |
| MX2022002324A (es) | Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos. | |
| UY39683A (es) | Anticuerpo dirigido a cd22 y cd79b | |
| DOP2025000059A (es) | Anticuerpos anti-lair1 humano | |
| CO2026003714A2 (es) | Anticuerpo que se une a c3bbb | |
| AR116101A1 (es) | Proteína de unión al antígeno anti-steap1 |